Fresenius Medical Care AG & Co. KGaA : Fresenius Medical Care successfully places senior notes

Fresenius Medical Care AG & Co. KGaA (the "company" or "Fresenius Medical Care"; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services, successfully placed three tranches of U.S. dollar and euro-denominated senior unsecured notes (together the "senior notes"). Proceeds amounting to approximately $1.82 billion are intended to be used for acquisitions, including the acquisition of Liberty Dialysis Holdings, Inc., to refinance indebtedness and for general corporate purposes.

The coupon for the dollar-denominated senior notes in the principal amount of $800 million due 2019 will be 5.625% and the coupon for the dollar-denominated senior notes in the principal amount of $700 million due 2022 will be 5.875%. The coupon for the euro-denominated senior notes in the principal amount of €250 million due 2019 will be 5.25%. All tranches were issued at par.

Michael Brosnan, chief financial officer of the company, commented: "This is the largest placement of senior notes in the history of Fresenius Medical Care and an important step in the financing of our growth strategy. We are very pleased to have successfully completed this offering at favorable rates in an overall challenging market environment. We believe this demonstrates that investors continue to recognize our financial stability and sustainable financial strength."

The dollar-denominated senior notes were offered by Fresenius Medical Care US Finance II, Inc. and the euro-denominated senior notes were offered by FMC Finance VIII S.A. Both issuers are wholly-owned subsidiaries of the company. The senior notes were offered through a private placement to institutional investors and will be guaranteed jointly and severally by the company and its subsidiaries, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care Deutschland GmbH.

The senior notes have not been registered under the Securities Act of 1933 as amended, but were offered to "qualified institutional buyers" (QIBs) in the U.S. pursuant to the exemption from registration provided by Rule 144A under the Securities Act and in exempted "offshore transactions" pursuant to Regulation S under the Securities Act. The senior notes may not be offered or sold in the U.S. unless registered under the Securities Act or pursuant to an applicable exemption from registration requirements.

Application has been made for admission of the senior notes to trading on the regulated market of the Luxembourg Stock Exchange.